An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Hoffmann-La Roche6,000 enrolled

Overview

This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta \[Neorecormon\] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.

Study Type

OBSERVATIONAL

Enrollment

6,000

Conditions

Anemia

Interventions

epoetin beta [NeoRecormon]DRUG

As prescribed by physician

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients \>/=18 years of age * Dialysis patients with chronic renal anemia * Written informed consent Exclusion Criteria: * Red blood cell transfusion in the previous 2 months * Severe neuropsychological disorder * Diabetic patients with serious complications This trial is being conducted in Morocco.

Locations (1)

Unnamed facility

Casablanca, Morocco

Outcomes

Primary Outcomes

Quality of life assessment: Kidney Disease Quality of Life Questionnaire

Time frame: Throughout study: 6 months

Secondary Outcomes

Evaluation of factors (demographic and social characteristics, dialysis method) influencing the quality of life

Time frame: Throughout study: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.